Biosimilars in Clinical Practice: Interchangeability and Extrapolation
As biosimilar guidance evolves in the United States and these biologics are studied and FDA-approved for use, it will be important for clinicians to understand how biosimilars’ characteristics overlap with, and differ from, other available biologic therapies, so that effective treatment selection and monitoring, and related patient education, can be achieved.
This site uses cookies. By continuing to use this website, you agree to their use. For details, please check our Privacy Policy.